Search Videos and More
News
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
News
Double Negative in Cells Could Undermine PARP Inhibitors
There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.
News
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
News
EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk
Dana-Farber Cancer Institute investigators launch a first-of-its-kind study to use a novel blood test to identify people who have never used tobacco but are at a high risk of lung cancer and offer them complimentary lung cancer screening.
News
New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor
A groundbreaking study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children.
News
Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival
Dana-Farber researchers have discovered ancient bacterial defenses and anti-defenses that may persist in some form in humans today and could provide insights into new approaches to cancer research and treatment.
News
What is Immunopeptidomics?
A burgeoning type of “omics” called immunopeptidomics is providing researchers with a powerful approach to discovering new ways to train a person’s immune system to fight cancer.
News
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.
News
Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025
Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.
News
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
News
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.